Follow
'In 2021, Jonathan Weissman, a biochemist at the Massachusetts Institute of Technology in Cambridge, and his colleagues developed CRISPRoff — an editing tool that adds a chemical tag, called a methyl group, to the DNA strand, which reduces gene activity without altering the genome. But the tool cannot be delivered to brain cells, because its genetic components are too large to fit into an adeno-associated virus (AAV) — a common vehicle for ferrying gene therapies inside cells. “The real challenge was delivery,” says Weissman.'
